Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: What the rheumatologist needs to know

Therapeutic Advances in Musculoskeletal Disease

Volumn 6, Issue 5, 2014, Pages 169-184

  Krause, Megan L ^a   Amin, Shreyasee ^a   Makol, Ashima ^b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

biologics; DMARDs; lactation; pregnancy; rheumatoid arthritis

Indexed keywords

ABATACEPT; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTHRALGIA; CONCEPTION; CONTRACEPTION; DISEASE ACTIVITY; DISEASE CONTROL; EMBRYOTOXICITY; FAMILY PLANNING; FOLLOW UP; HUMAN; LACTATION; MALE FERTILITY; MALE STERILITY; MATERIAL SAFETY DATA SHEET; PATIENT COUNSELING; PATIENT RISK; PHYSICIAN; PREGNANCY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; TIME TO PREGNANCY;

EID: 84910036466     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X14551568     Document Type: Review

References (95)

1. Amin S. Peterson E. Reed A. Mueller D. (2011) Pregnancy and rheumatoid arthritis: insights into the immunology of fetal tolerance and control of autoimmunity. Curr Rheumatol Rep 13: 449–455.
2. Ban L. Tata L. Fiaschi L. Card T. (2014) Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology 146: 76–84.
3. Barrett J. Brennan P. Fiddler M. Silman A. (1999) Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheumatism 42: 1219–1227.
4. Bay Bjorn A. Ehrenstein V. Holmager Hundborg H. Aagaard Nohr E. Toft Sorensen H. Norgaard M. (2014) Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Therapeut 21 (2): 73–80.
5. Beghin D. Cournot M. Vauzelle C. Elefant E. (2011) Paternal exposure to methotrexate and pregnancy outcomes. J Rheumatol 38: 628–632.
6. Beitins I. Bayard F. Ances I. Kowarski A. Migeon C. (1972) The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatrics 81: 936–945.
7. Ben-Horin S. Yavzori M. Katz L. Picard O. Fudim E. Chowers Y. et al. (2010) Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 8: 475–476.
8. Berger C. Recher M. Steiner U. Hauser T. (2009) A patient's wish: anakinra in pregnancy. Ann Rheumatic Dis 68: 1794–1795.
9. Berthelot J. de Bandt M. Goupille P. Solau-Gervais E. Liote F. Goeb V. et al. (2009) Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76: 28–34.
10. Bjorn A. Nielsen R. Norgaard M. Nohr E. Ehrenstein V. (2013) Risk of miscarriage among users of corticosteroid hormones: a population-based nested case-control study. Clin Epidemiol 5: 287–294.
11. Branski D. Kerem E. Gross-Kieselstein E. Hurvitz H. Litt R. Abrahamov A. (1986) Bloody diarrhea - a possible complication of sulfasalazine transferred through human breast milk. J Pediatric Gastroenterol Nutrition 5: 316–317.
12. Brent R. (2001) Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 63: 106–112.
13. Buchanan N. Toubi E. Khamashta M. Lima F. Kerslake S. Hughes G. (1996) Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheumatic Dis 55: 486–488.
14. Buckley L. Bullaboy C. Leichtman L. Marquez M. (1997) Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheumatism 40: 971–973.
15. Carter J. Ladhani A. Ricca L. Valeriano J. Vasey F. (2009) A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database.J Rheumatol 36: 635–641.
16. Carter J. Valeriano J. Vasey F. (2006) Tumor necrosis factor-alpha inhibition and vater association: a causal relationship. J Rheumatol 33: 1014–1017.
17. Cassina M. Johnson D. Robinson L. Braddock S. Xu R. Jimenez J. et al. (2012) Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheumatism 64: 2085–2094.
18. Chakravarty E. Murray E. Kelman A. Farmer P. (2011) Pregnancy outcomes after maternal exposure to rituximab. Blood 117: 1499–1506.
19. Chakravarty E. Sanchez-Yamamoto D. Bush T. (2003) The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 30: 241–246.
20. Chambers C. Johnson D. Robinson L. Braddock S. Xu R. Lopez-Jimenez J. et al. (2010) Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheumatism 62: 1494–1503.
21. Clowse M. Magder L. Witter F. Petri M. (2006) Hydroxychloroquine in lupus pregnancy. Arthritis Rheumatism 54: 3640–3647.
22. Committee on Drugs, American Academy of Pediatrics (2001) Transfer of drugs and other chemicals into human milk. Pediatrics 108: 776–789.
23. Costedoat-Chalumeau N. Amoura Z. Aymard G. Le T. Wechsler B. Vauthier D. et al. (2002) Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheumatism 46: 1123–1124.
24. Costedoat-Chalumeau N. Amoura Z. Duhaut P. Huong D. Sebbough D. Wechsler B. et al. (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheumatism 48: 3207–3211.
25. Cowchock F. Reece E. Balaban D. Branch D. Plouffe L. (1992) Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstetrics Gynecol 166: 1318–1323.
26. de Man Y. Dolhain R. van de Geijn F. Willemsen S. Hazes J. (2008) Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheumatism 59: 1241–1248.
27. de Santis M. Straface G. Cavaliere A. Carducci B. Caruso A. (2005) Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann Rheumatic Dis 64: 1096–1097.
28. Diav-Citrin O. Blyakhman S. Shechtman S. Ornoy A. (2013) Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. Reprod Toxicol 39: 58–62.
29. Diav-Citrin O. Otcheretianski-Volodarsky A. Shechtman S. Ornoy A. (2014) Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol 43: 78–84.
30. Edwards D. Aldridge T. Baird D. Funk M. Savitz D. Hartmann K. (2012) Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion. Obstetrics Gynecol 120: 113–122.
31. Esbjorner E. Jarnerot G. Wranne L. (1987) Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paed Scand 76: 137–142.
32. Fukushima R. Kanamori S. Hirashiba M. Hishikawa A. Muranaka R. Kaneto M. et al. (2007) Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor leflunomide in mice. Reprod Toxicol 24: 310–316.
33. Goldstein L. Dolinsky G. Greenberg R. Schaefer C. Cohen-Kerem R. Diav-Citrin O. et al. (2007) Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A 79: 696–701.
34. Hausknecht R. (1995) Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med 333: 537–540.
35. Hench P. (1938) The ameliorating of pregnancy on chronic atrophic (infectious, rheumatoid) arthritis, fibrositis and intermittent hydrarthrosis. Proc Staff Meet Mayo Clin 13: 161–167.
36. Hickok D. Hollenbach K. Reilley S. Nyberg D. (1989) The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am J Obstetrics Gynecol 160: 1525–1530; discussion 1530–1521.
37. Hviid A. Molgaard-Nielsen D. (2011) Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 183: 796–804.
38. Hyrich K. Symmons D. Watson K. Silman A. (2006) Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheumatism 54: 2701–2702.
39. Jansen G. van der Heijden J. Oerlemans R. Lems W. Ifergan I. Scheper R. et al. (2004) Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheumatism 50: 2130–2139.
40. Jarnerot G. Into-Malmberg M. Esbjorner E. (1981) Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scand J Gastroenterol 16: 693–697.
41. Johns D. Rutherford L. Leighton P. Vogel C. (1972) Secretion of methotrexate into human milk. Am J Obstetrics Gynecol 112: 978–980.
42. Kane S. Ford J. Cohen R. Wagner C. (2009) Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 43: 613–616.
43. Katz J. Antoni C. Keenan G. Smith D. Jacobs S. Lichtenstein G. (2004) Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 99: 2385–2392.
44. Koren G. Florescu A. Costei A. Boskovic R. Moretti M. (2006) Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother 40: 824–829.
45. Kozlowski R. Steinbrunner J. Mackenzie A. Clough J. Wilke W. Segal A. (1990) Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 88: 589–592.
46. Kuriya B. Hernandez-Diaz S. Liu J. Bermas B. Daniel G. Solomon D. (2011) Patterns of medication use during pregnancy in rheumatoid arthritis. Arthritis Care Res 63: 721–728.
47. Levi S. Liberman M. Levi A. Bjarnason I. (1988) Reversible congenital neutropenia associated with maternal sulphasalazine therapy. Eur J Pediatrics 148: 174–175.
48. Lewden B. Vial T. Elefant E. Nelva A. Carlier P. Descotes J. (2004) Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol 31: 2360–2365.
49. Li D. Liu L. Odouli R. (2003) Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 327: 368.
50. Lichtenstein G. Feagan B. Cohen R. Salzberg B. Diamond R. Price S. et al. (2012) Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the treat registry. Am J Gastroenterol 107: 1409–1422.
51. Lloyd M. Carr M. Mcelhatton P. Hall G. Hughes R. (1999) The effects of methotrexate on pregnancy, fertility and lactation. QJM 92: 551–563.
52. Mahadevan U. Wolf D. Dubinsky M. Cortot A. Lee S. Siegel C. et al. (2013) Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11: 286–292; quiz e224.
53. Makol A. Wright K. Amin S. (2011) Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs 71: 1973–1987.
54. Marchioni R. Lichtenstein G. (2013) Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol 19: 2591–2602.
55. Mogadam M. Dobbins W. III Korelitz B. Ahmed S. (1981) Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 80: 72–76.
56. Momma K. Hagiwara H. Konishi T. (1984) Constriction of fetal ductus arteriosus by non-steroidal anti-inflammatory drugs: study of additional 34 drugs. Prostaglandins 28: 527–536.
57. Momma K. Takeuchi H. (1983) Constriction of fetal ductus arteriosus by non-steroidal anti-inflammatory drugs. Prostaglandins 26: 631–643.
58. Moskovitz D. Bodian C. Chapman M. Marion J. Rubin P. Scherl E. et al. (2004) The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. AM J Gastroenterol 99: 656–661.
59. Murashima A. Watanabe N. Ozawa N. Saito H. Yamaguchi K. (2009) Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheumatic Dis 68: 1793–1794.
60. Nakhai-Pour H. Broy P. Sheehy O. Berard A. (2011) Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ 183: 1713–1720.
61. Nelson J. Ostensen M. (1997) Pregnancy and rheumatoid arthritis. Rheumatic Dis Clin North Am 23: 195–212.
62. Nielsen G. Sorensen H. Larsen H. Pedersen L. (2001) Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 322: 266–270.
63. Nielsen O. Loftus E. Jr Jess T. (2013) Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review. BMC Med 11: 174.
64. Norgard B. Czeizel A. Rockenbauer M. Olsen J. Sorensen H. (2001) Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 15: 483–486.
65. Norgard B. Pedersen L. Christensen L. Sorensen H. (2007) Therapeutic drug use in women with crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 102: 1406–1413.
66. O'morain C. Smethurst P. Dore C. Levi A. (1984) Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 25: 1078–1084.
67. Ogueh O. Johnson M. (2000) The metabolic effect of antenatal corticosteroid therapy. Human Reprod Update 6: 169–176.
68. Ojeda-Uribe M. Afif N. Dahan E. Sparsa L. Haby C. Sibilia J. et al. (2013) Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol 32: 695–700.
69. Ost L. Wettrell G. Bjorkhem I. Rane A. (1985) Prednisolone excretion in human milk. J Pediatrics 106: 1008–1011.
70. Ostensen M. Forger F. (2009) Management of RA medications in pregnant patients. Nat Rev Rheumatol 5: 382–390.
71. Ostensen M. Hartmann H. Salvesen K. (2000) Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol 27: 1872–1875.
72. Ostensen M. Khamashta M. Lockshin M. Parke A. Brucato A. Carp H. et al. (2006) Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 8: 209.
73. Ostensen M. Villiger P. (2007) The remission of rheumatoid arthritis during pregnancy. Sem Immunopathol 29: 185–191.
74. Ostensen M. Von Esebeck M. Villiger P. (2007) Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol 34: 1266–1269.
75. Oussalah A. Bigard M. Peyrin-Biroulet L. (2009) Certolizumab use in pregnancy. Gut 58: 608.
76. Park-Wyllie L. Mazzotta P. Pastuszak A. Moretti M. Beique L. Hunnisett L. et al. (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62: 385–392.
77. Parke A. West B. (1996) Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 23: 1715–1718.
78. Paschou S. Voulgari P. Vrabie I. Saougou I. Drosos A. (2009) Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. J Rheumatol 36: 351–354.
79. Pendergraft W. III Mcgrath M. Murphy A. Murphy P. Laliberte K. Greene M. et al. (2013) Fetal outcomes after rituximab exposure in women with autoimmune vasculitis. Ann Rheumatic Dis 72: 2051–2053.
80. Powell H. Ekert H. (1971) Methotrexate-induced congenital malformations. Med J Australia 2: 1076–1077.
81. Rahimi R. Nikfar S. Rezaie A. Abdollahi M. (2008) Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 25: 271–275.
82. Rosandich P. Kelley J. III Conn D. (2004) Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers. Curr Opin Rheumatol 16: 192–198.
83. Rubbert-Roth A. Goupille P. Moosavi S. Hou A. (2010) First experiences with pregnancies in RA patients receiving tocilizumab therapy. Arthritis Rheumatism (November Suppl.): abstract 384.
84. Said T. Agarwal A. Falcone T. Sharma R. Bedaiwy M. Li L. (2005) Infliximab may reverse the toxic effects induced by tumor necrosis factor alpha in human spermatozoa: an in vitro model. Fertility Sterility 83: 1665–1673.
85. Sangle S. Lutalo P. Davies R. Khamashta M. D'cruz D. (2013) B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. J Autoimmun 43: 55–59.
86. Sau A. Clarke S. Bass J. Kaiser A. Marinaki A. Nelson-Piercy C. (2007) Azathioprine and breastfeeding: is it safe? BJOG 114: 498–501.
87. Singh J. Furst D. Bharat A. Curtis J. Kavanaugh A. Kremer J. et al. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64: 625–639.
88. Sperber K. Hom C. Chao C. Shapiro D. Ash J. (2009) Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatric Rheumatol 7: 9.
89. Suominen J. Wang Y. Kaipia A. Toppari J. (2004) Tumor necrosis factor-alpha (TNF-alpha) promotes cell survival during spermatogenesis, and this effect can be blocked by infliximab, a TNF-alpha antagonist. Eur J Endocrinol 151: 629–640.
90. Sussman A. Leonard J. (1980) Psoriasis, Methotrexate, and Oligospermia. Archives of dermatology 116: 215–217.
91. Takahashi Y. Roman C. Chemtob S. Tse M. Lin E. Heymann M. et al. (2000) Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo. Am J Physiol 278: R1496–R1505.
92. Temprano K. Bandlamudi R. Moore T. (2005) Antirheumatic drugs in pregnancy and lactation. Sem Arthritis Rheumatism 35: 112–121.
93. Vasiliauskas E. Church J. Silverman N. Barry M. Targan S. Dubinsky M. (2006) Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 4: 1255–1258.
94. Villiger P. Caliezi G. Cottin V. Forger F. Senn A. Ostensen M. (2010) Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheumatic Dis 69: 1842–1844.
95. Vinet E. Kuriya B. Pineau C. Clarke A. Bernatsky S. (2013) Induced abortions in women with rheumatoid arthritis receiving methotrexate. Arthritis Care Res 65: 1365–1369.